Raymond James Financial
ONCY

Raymond James Financial’s Oncolytics Biotech ONCY Stock Holding History

Raymond James Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.3K Buy
36,086
+2,335
+7% +$2.17K ﹤0.01% 5292
2026
Q1 		$28.6K Buy
33,751
+383
+1% +$381 ﹤0.01% 5182
2025
Q4 		$29.2K Buy
+33,368
New +$36.1K ﹤0.01% 5057
2025
Q3 		– Sell
-6,450
Closed -$4.99K – 6186
2025
Q2 		$4.99K Buy
+6,450
New +$3.42K ﹤0.01% 6173

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Raymond James Financial's ONCY Position: Q2 2026 in Review

Raymond James Financial increased its Oncolytics Biotech (ONCY) stake by 6.9% in Q2 2026, buying an estimated $2.17K and bringing the position to 36,086 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5292.

Raymond James Financial first reported a position in ONCY in Q2 2025 and has held it in 4 quarters since. 76 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Raymond James Financial held 36,086 shares of Oncolytics Biotech worth $34.3K as of Q2 2026.
  • Raymond James Financial bought 2,335 Oncolytics Biotech shares in Q2 2026, an estimated $2.17K.
  • Oncolytics Biotech made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5292 holding.
  • Raymond James Financial first reported a position in Oncolytics Biotech in Q2 2025 and has held it in 4 quarters since.
  • 76 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.